Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

PI3K inhibition highlights new molecular interactions involved in the skeletogenesis of Paracentrotus lividus embryos.

Chiaramonte M, Russo R, Costa C, Bonaventura R, Zito F.

Biochim Biophys Acta Mol Cell Res. 2019 Sep 13:118558. doi: 10.1016/j.bbamcr.2019.118558. [Epub ahead of print]

PMID:
31525406
2.

Stress and immune response to bacterial LPS in the sea urchin Paracentrotus lividus (Lamarck, 1816).

Chiaramonte M, Inguglia L, Vazzana M, Deidun A, Arizza V.

Fish Shellfish Immunol. 2019 Sep;92:384-394. doi: 10.1016/j.fsi.2019.06.017. Epub 2019 Jun 17.

PMID:
31220574
3.

Evolutionary conserved pathway of the innate immune response after a viral insult in Paracentrotus lividus sea urchin.

Chiaramonte M, Arizza V, Russo R.

Int J Immunogenet. 2019 Jun;46(3):192-202. doi: 10.1111/iji.12424. Epub 2019 Apr 2.

PMID:
30938047
4.

NF-YA enters cells through cell penetrating peptides.

Libetti D, Bernardini A, Chiaramonte ML, Minuzzo M, Gnesutta N, Messina G, Dolfini D, Mantovani R.

Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):430-440. doi: 10.1016/j.bbamcr.2018.10.004. Epub 2018 Oct 6.

PMID:
30296497
5.

Response to metals treatment of Fra1, a member of the AP-1 transcription factor family, in P. lividus sea urchin embryos.

Russo R, Bonaventura R, Chiaramonte M, Costa C, Matranga V, Zito F.

Mar Environ Res. 2018 Aug;139:99-112. doi: 10.1016/j.marenvres.2018.05.003. Epub 2018 May 5.

PMID:
29776592
6.

Nickel toxicity in P. lividus embryos: Dose dependent effects and gene expression analysis.

Bonaventura R, Zito F, Chiaramonte M, Costa C, Russo R.

Mar Environ Res. 2018 Aug;139:113-121. doi: 10.1016/j.marenvres.2018.05.002. Epub 2018 May 4.

PMID:
29773318
7.

Cytotoxic activity of Holothuria tubulosa (Echinodermata) coelomocytes.

Vazzana M, Celi M, Chiaramonte M, Inguglia L, Russo D, Ferrantelli V, Battaglia D, Arizza V.

Fish Shellfish Immunol. 2018 Jan;72:334-341. doi: 10.1016/j.fsi.2017.11.021. Epub 2017 Nov 12.

PMID:
29138098
8.

Antibacterial Activity of Desert Truffles from Saudi Arabia Against Staphylococcus aureus and Pseudomonas aeruginosa.

Schillaci D, Cusimano MG, Cascioferro SM, Di Stefano V, Arizza V, Chiaramonte M, Inguglia L, Bawadekji A, Davino S, Gargano ML, Venturella G.

Int J Med Mushrooms. 2017;19(2):121-125. doi: 10.1615/IntJMedMushrooms.v19.i2.30.

PMID:
28436320
9.

LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.

Krönung SK, Beyer U, Chiaramonte ML, Dolfini D, Mantovani R, Dobbelstein M.

Oncotarget. 2016 Jun 7;7(23):33484-97. doi: 10.18632/oncotarget.9255.

10.

NF-Y activates genes of metabolic pathways altered in cancer cells.

Benatti P, Chiaramonte ML, Lorenzo M, Hartley JA, Hochhauser D, Gnesutta N, Mantovani R, Imbriano C, Dolfini D.

Oncotarget. 2016 Jan 12;7(2):1633-50. doi: 10.18632/oncotarget.6453.

11.

Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.

Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U; Italian Liver Cancer Group.

Liver Transpl. 2015 Oct;21(10):1250-8. doi: 10.1002/lt.24214.

12.

A member of the Tlr family is involved in dsRNA innate immune response in Paracentrotus lividus sea urchin.

Russo R, Chiaramonte M, Matranga V, Arizza V.

Dev Comp Immunol. 2015 Aug;51(2):271-7. doi: 10.1016/j.dci.2015.04.007. Epub 2015 Apr 20.

PMID:
25907136
13.

Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme.

Pasquale L, Giorgi Rossi P, Carozzi F, Pedretti C, Ruggeri C, Scalvinoni V, Cotti Cottini M, Tosini A, Morana C, Chiaramonte M, Sacristani M, Cirelli R, Chiudinelli D, Piccolomini M, Marchione R, Romano L, Domenighini S, Pieracci G, Confortini M.

J Med Screen. 2015 Mar;22(1):38-48. doi: 10.1177/0969141314561707. Epub 2014 Nov 27.

PMID:
25431452
14.

Prognosis of untreated hepatocellular carcinoma.

Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2015 Jan;61(1):184-90. doi: 10.1002/hep.27443. Epub 2014 Nov 26.

PMID:
25234419
15.

Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Carr BI, Pancoska P, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Semin Oncol. 2014 Jun;41(3):406-414. doi: 10.1053/j.seminoncol.2014.04.002. Epub 2014 Apr 24.

16.

Low alpha-fetoprotein HCC and the role of GGTP.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F.

Int J Biol Markers. 2014 Dec 9;29(4):e395-402. doi: 10.5301/jbm.5000092.

PMID:
24832180
17.

Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Ludovico Rapaccini G, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Semin Oncol. 2014 Apr;41(2):252-8. doi: 10.1053/j.seminoncol.2014.03.006. Epub 2014 Mar 6.

18.

Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.

Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1927-33.e2. doi: 10.1016/j.cgh.2014.02.025. Epub 2014 Feb 26.

PMID:
24582947
19.

Significance of platelet and AFP levels and liver function parameters for HCC size and survival.

Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer Group.

Int J Biol Markers. 2014 Sep 30;29(3):e215-23. doi: 10.5301/jbm.5000064.

PMID:
24526315
20.

Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres.

Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Poggio PD, Rapaccini G, Nolfo AM, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Foschi FG, Cabibbo G, Felder M, Ciccarese F, Missale G, Baroni GS, Morisco F, Pecorelli A, Farinati F; Italian Liver Cancer (ITA.LI.CA) Group.

Liver Int. 2013 Oct;33(9):1420-7. doi: 10.1111/liv.12208. Epub 2013 Jun 12.

PMID:
23758775
21.

Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients.

Giannini EG, Savarino V, Farinati F, Ciccarese F, Rapaccini G, Marco MD, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2013 Nov;33(10):1594-600. doi: 10.1111/liv.12199. Epub 2013 May 8.

PMID:
23654354
22.

Hepatocellular carcinoma in patients without cirrhosis in Italy.

Giannini EG, Marenco S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F.

Dig Liver Dis. 2013 Feb;45(2):164-9. doi: 10.1016/j.dld.2012.08.018. Epub 2012 Oct 7.

PMID:
23047000
23.

Ten-year outcome of radiofrequency thermal ablation for hepatocellular carcinoma: an Italian experience.

Giannini EG, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Am J Gastroenterol. 2012 Oct;107(10):1588-9; author reply 1590. doi: 10.1038/ajg.2012.250. No abstract available.

PMID:
23034617
24.

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.

Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Costa P, Rendina M, Ancarani F, Chiaramonte M, Verucchi G, Craxì A, Bernardi M, Andreone P; AISF HepaElder Study Group.

Dig Liver Dis. 2012 Aug;44(8):674-80. doi: 10.1016/j.dld.2012.03.009. Epub 2012 Apr 25.

PMID:
22538206
25.

Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.

Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Hepatology. 2012 Oct;56(4):1371-9. doi: 10.1002/hep.25814.

PMID:
22535689
26.

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, Federico A.

Free Radic Biol Med. 2012 May 1;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008. Epub 2012 Feb 15.

PMID:
22343419
27.

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2012 May;56(5):1089-96. doi: 10.1016/j.jhep.2011.11.022. Epub 2012 Jan 13.

PMID:
22245900
28.

The changing scenario of hepatocellular carcinoma over the last two decades in Italy.

Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F.

J Hepatol. 2012 Feb;56(2):397-405. doi: 10.1016/j.jhep.2011.05.026. Epub 2011 Jul 12.

PMID:
21756850
29.

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.

Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group.

Lancet Oncol. 2011 Jul;12(7):654-62. doi: 10.1016/S1470-2045(11)70144-9. Epub 2011 Jun 16.

PMID:
21684210
30.

Relative decrease in the role played by hepatitis B virus infection in the aetiology of hepatocellular carcinoma during a 20-year period: a multicentre Italian study.

Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group.

Liver Int. 2011 Feb;31(2):192-6. doi: 10.1111/j.1478-3231.2010.02409.x. Epub 2010 Dec 10.

PMID:
21143580
31.

Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload.

Floreani A, Navaglia F, Rizzotto ER, Basso D, Chiaramonte M, Padoan A, Petridis I, Cazzagon N, Testa R, Marra M, Plebani M.

Clin Chem Lab Med. 2011 Feb;49(2):197-206. doi: 10.1515/CCLM.2011.055. Epub 2010 Dec 14.

PMID:
21143008
32.

A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre.

Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, Cazzagon N, Brombin C, Salmaso L, Baldo V.

Liver Int. 2011 Mar;31(3):361-8. doi: 10.1111/j.1478-3231.2010.02366.x. Epub 2010 Nov 8. Erratum in: Liver Int. 2011 Apr;31(4):588.

PMID:
21059170
33.

Early acid perception in NERD.

Frieri G, Antonini F, Tanga M, Saltarelli P, Melideo D, Chiaramonte M.

Dis Esophagus. 2011 Feb;24(2):127-30. doi: 10.1111/j.1442-2050.2010.01105.x. Epub 2010 Sep 2.

PMID:
20819099
34.

The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis.

Niese KA, Chiaramonte MG, Ellies LG, Rothenberg ME, Zimmermann N.

Respir Res. 2010 Jun 24;11:87. doi: 10.1186/1465-9921-11-87.

35.

Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.

Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2010 Aug;53(2):291-7. doi: 10.1016/j.jhep.2010.03.010. Epub 2010 Apr 27.

PMID:
20483497
36.

Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: between the devil and the deep blue sea.

Giannini EG, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer group.

Liver Int. 2010 Jul;30(6):923-4; author reply 924-5. doi: 10.1111/j.1478-3231.2010.02220.x. Epub 2010 Mar 8. No abstract available.

PMID:
20214738
37.

Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma.

Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):493-501. doi: 10.1111/j.1365-2036.2009.04198.x. Epub 2009 Nov 14. Erratum in: Aliment Pharmacol Ther. 2010 Apr;31(7):770.

38.

Hepatocellular carcinoma in patients with cryptogenic cirrhosis.

Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group.

Clin Gastroenterol Hepatol. 2009 May;7(5):580-5. doi: 10.1016/j.cgh.2009.01.001.

PMID:
19418607
39.

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection.

Taliani G, Rucci P, Biliotti E, Cirrincione L, Aghemo A, Alberti A, Almasio PL, Bartolozzi D, Caporaso N, Coppola R, Chiaramonte M, Floreani A, Gaeta GB, Persico M, Secchi G, Versace I, Zacharia S, Mele A.

J Viral Hepat. 2007 Dec;14(12):875-82.

PMID:
18070291
40.

An open population screening study for HFE gene major mutations proves the low prevalence of C282Y mutation in Central Italy.

Floreani A, Rosa Rizzotto E, Basso D, Navaglia F, Zaninotto M, Petridis I, DI Andrea O, Testa R, Marra M, Baldo V, Chiaramonte M.

Aliment Pharmacol Ther. 2007 Aug 15;26(4):577-86.

41.

Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung.

Rothenberg ME, Doepker MP, Lewkowich IP, Chiaramonte MG, Stringer KF, Finkelman FD, MacLeod CL, Ellies LG, Zimmermann N.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14895-900. Epub 2006 Sep 26.

42.

Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence.

Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, Hennig BJ, Hellier S, Knapp S, Wright M, Chiaramonte M, Bell JI, Graves M, Whittle HC, Thomas HC, Thursz MR, Hill AV.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9148-53. Epub 2006 Jun 6.

43.

Is hepatitis C virus a risk factor for thyroid autoimmunity?

Floreani A, Betterle C, Carderi I, Presotto F, Pedini B, Moscon A, Andrea O, Chiaramonte M; Arsita-one Research Group.

J Viral Hepat. 2006 Apr;13(4):272-7.

PMID:
16611194
44.

Smad3 knock-out mice as a useful model to study intestinal fibrogenesis.

Zanninelli G, Vetuschi A, Sferra R, D'Angelo A, Fratticci A, Continenza MA, Chiaramonte M, Gaudio E, Caprilli R, Latella G.

World J Gastroenterol. 2006 Feb 28;12(8):1211-8.

45.

Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life.

Rucci P, Taliani G, Cirrincione L, Alberti A, Bartolozzi D, Caporaso N, Colombo M, Coppola R, Chiaramonte M, Craxi A, De Sio I, Floreani AR, Gaeta GB, Persico M, Secchi G, Versace I, Mele A.

Dig Liver Dis. 2005 Nov;37(11):850-60. Epub 2005 Oct 10.

PMID:
16221576
46.

Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis.

Addis-Lieser E, Köhl J, Chiaramonte MG.

J Immunol. 2005 Aug 1;175(3):1894-902.

47.

Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.

Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, Chiaramonte M, Caprilli R.

Dig Liver Dis. 2005 Feb;37(2):92-6.

PMID:
15733520
48.

Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance.

Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, Thursz MR.

J Viral Hepat. 2004 Sep;11(5):459-64.

PMID:
15357653
49.

P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon gamma and the IL-13 decoy receptor.

Wynn TA, Hesse M, Sandler NG, Kaviratne M, Hoffmann KF, Chiaramonte MG, Reiman R, Cheever AW, Sypek JP, Mentink-Kane MM.

Hepatology. 2004 Mar;39(3):676-87.

PMID:
14999686
50.

Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study.

Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, Colucci G, Rizzetto M.

J Hepatol. 2003 Dec;39(6):1036-41.

PMID:
14642623

Supplemental Content

Loading ...
Support Center